Received Aug 18, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 2 | AHBVD184AC | — |
administration of a late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 32-year-old male patient who received HBV (Engerix B) (batch number AHBVD184AC) for prophylaxis. Previously administered products included Engerix b (received first dose in DEC-2024). On 08-AUG-2025, the patient received the 2nd dose of Engerix B. On 08-AUG-2025, an unknown time after receiving Engerix B, the patient experienced drug dose administration interval too long (Verbatim: administration of a late second dose). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 08-AUG-2025 The pharmacist called to report the administration of a late second dose of the Engerix-B vaccine to a male patient who received the first dose back in December 2024 and she wanted to know what the schedule for the third shot is. The patient received 2nd dose of Engerix B, later than the recommended interval, which led to lengthening of vaccinations schedule.